Lyvgen Biopharma Holdings Limited
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Lyvgen Biopharma Holdings Limited sits in the upper half of US sponsors by registered trial count (#4,887 of 15,751 sponsors by registered trial count).
Lyvgen Biopharma Holdings Limited: 2 sponsored US clinical trials, none currently recruiting.
Lyvgen Biopharma Holdings Limited sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 2 trials.
Mid-pack sponsor footprint
Lyvgen Biopharma Holdings Limited is in the upper half of sponsors by trial count (#4,887 of 15,751 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
NCT04635995
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
NCT04130542
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
How the Lyvgen Biopharma Holdings Limited early-phase archive is shaped
2 indexed studies, none listed as recruiting (0% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Cancer (2 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.